GlassScriptPhysician profile
Sonali A Khond
NPI 1023089885
$6,516.49
in general payments reported to CMS, 2019-2025
40 companies · $2,698 in 2025
The $2,698 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.89 · 2022: $54.85 · 2023: $748 · 2024: $2,975 · 2025: $2,698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,421.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $956.86 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $938.30 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $733.31 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $377.16 | 2023-2024 | |
| Pfizer INC. | $341.84 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $303.91 | 2024-2025 | |
| Eisai INC. | $253.70 | 2024-2025 | |
| Amgen INC. | $247.27 | 2023-2025 | Evenity, Prolia, Prolia |
| Sumitomo Pharma America, INC. | $244.25 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $201.53 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| E.R. Squibb & Sons, L.L.C. | $180.74 | 2023-2025 | Eliquis, Camzyos |
| Phathom Pharmaceuticals, INC. | $178.03 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $139.76 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $139.37 | 2024 | |
| Janssen Pharmaceuticals, INC | $118.22 | 2023-2024 | Xarelto |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $112.48 | 2023-2025 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.58 | 2023-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $87.96 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Kowa Pharmaceuticals America, INC. | $77.00 | 2024-2025 | Zoryve |
| Paratek Pharmaceuticals, INC. | $70.90 | 2023-2024 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $65.46 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.82 | 2023-2025 | Jardiance, Ofev |
| Tolmar, INC. | $61.66 | 2025 | Jatenzo |
| Boston Scientific Corporation | $46.12 | 2024 | |
| Dexcom, INC. | $45.42 | 2024 | Dexcom G6 Transmitter |
| Biogen, INC. | $43.55 | 2024-2025 | Leqembi |
| Lucid Diagnostics INC. | $42.49 | 2024-2025 | |
| Coloplast Corp | $39.89 | 2019 | |
| Lundbeck LLC | $38.25 | 2024-2025 | Rexulti |
| Verona Pharma, INC. | $37.33 | 2025 | Ohtuvayre |
| Esperion Therapeutics, INC. | $27.90 | 2024-2025 | Nexletol |
| Inspire Medical Systems, INC. | $27.32 | 2025 | Inspire |
| Hologic Sales and Service, LLC | $22.51 | 2025 | Aptima, Thinprep 2000 Processor |
| Mylan Specialty L.P. | $21.32 | 2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $20.66 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $20.64 | 2025 | Gvoke Hypopen |
| Life Molecular Imaging LTD | $20.29 | 2025 | Neuraceq |
| Rgh Enterprises LLC | $20.10 | 2025 | |
| Madrigal Pharmaceuticals | $18.57 | 2024 | Resmetirom |
| Scpharmaceuticals INC. | $18.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonali Khond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.